Neuropace Financials
| NPCE Stock | USD 15.32 0.29 1.86% |
Neuropace | Build AI portfolio with Neuropace Stock |
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Neuropace Stock Summary
Neuropace competes with Cerus, Rxsight, CVRx, 908 Devices, and Brainsway. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people.| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US6412881053 |
| Business Address | 455 North Bernardo |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.neuropace.com |
| Phone | 650 237 2700 |
| Currency | USD - US Dollar |
Neuropace Key Financial Ratios
| Return On Equity | -1.69 | |||
| Return On Asset | -0.11 | |||
| Target Price | 19.38 | |||
| Number Of Employees | 209 | |||
| Beta | 1.86 |
Neuropace Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neuropace's current stock value. Our valuation model uses many indicators to compare Neuropace value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuropace competition to find correlations between indicators driving Neuropace's intrinsic value. More Info.Neuropace is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuropace by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Neuropace Financials
What exactly are Neuropace Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Neuropace's income statement, its balance sheet, and the statement of cash flows. Potential Neuropace investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Neuropace investors may use each financial statement separately, they are all related. The changes in Neuropace's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neuropace's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Neuropace January 30, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neuropace help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuropace. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuropace based on widely used predictive technical indicators. In general, we focus on analyzing Neuropace Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuropace's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.54 | |||
| Information Ratio | 0.136 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 6.3 |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |